Reference | Country | Research design | Cases | Results | Follow-up |
31 | Sweden | prospective nested case-control | 1226 | The risk of cervical squamous cell carcinoma tripled within 7 years in patients who initially tested positive for non-16/18 HR-HPV than that for the HPV negative women. | 7 years |
32 | Sweden | prospective multicenter study | 5696 | HPV-31 and HPV-33 positive women had a higher risk of CIN2+ than HPV-18 positive women. | 4.1 years |
33 | USA | prospective multicenter study | 27,037 | HPV-16 and 31 have the highest risk of CIN2+ and CIN3+, and are most common in CIN2+ and CIN3+ cases. HPV-18, 33/58 and 52 constitute the intermediate risk range, and 45, 51, 35/39/68 and 56/59/66 have the lowest risk. | 3 years |
34 | USA | prospective cohort study | 167 | The cytology in LSILs, patients with HPV-31, HPV-39, and HPV-52 infections had a high incidence of HSILs. | 20–46 months |
35 | Korea | retrospective study | 1102 | HPV-31/33/35/45/52/58 genotypes are more likely to develop into HSIL or cervical cancer. | 30 months |
5 | USA | prospective multicenter study | 2807 | When cytological examination results showed ASC-US or LSILs at baseline, HPV-16 had the highest risk of CIN2+, HPV-31, HPV-18, HPV-33/58, HPV-51, and HPV-52 were in the middle risk range, and HPV-35/39/68, HPV-45, and HPV-56/59/66 had the lowest risk of CIN2+. | 3 years |
36 | China | retrospective study | 902 | Women with cytological LSIL combined with HR-HPV-16/18/31/33/52/58 positive results should be recommended for colposcopy. | 3 years |
37 | Denmark | prospective cohort study | 8656 | The risk associated with HPV-16 was the highest to develop into CIN3+, followed by HPV-18, HPV-33, and HPV-31. | 12 years |
38 | Turkey | retrospective study | 179 | HPV-31 has the highest risk of developing CIN2+ among non-16/18 HPV genotypes. | 2 years |
39 | Thailand | cross-sectional study | 5433 | The detection rate of HSIL + could be increased by adding HPV-52/58 or HPV-31/52/58 genotyping to HPV-16/18 genotyping. | 7 months |
40 | China | cross-sectional study | 3997 | HPV-16/18/33/52/58 showed a high sensitivity and specificity in detecting CIN2+ in ASCUS patients. | 2 months |
41 | China | prospective observational study | 19207 | HPV-16/18/31/33/52/58 genotype positive patients have a high risk of CIN2+. | 3 years |
42 | Japan | prospective cohort study | 570 | Women with cytological LSIL and histological CIN1-2 lesions, the cumulative probability of developing CIN 3 within 5 years was 20.5% for HPV16, 18, 31, 33, 35, 52, and 58. | 39.1 months |